7
Cordlife Group Limited
Annual Report 2016
Moving forward, we continue to be on the lookout for the
next break in other fast-growing markets to expand our
geographical footprint as one of our key growth drivers
while we remain on track to do what we do best for long-
term business growth.
Enhancing Our Value Proposition
As part of our commitment to uphold quality, our facility
in Singapore was accredited in December 2015 by
FACT-Netcord, making us one out of the only six private
cord blood banks in the world with double-accreditation
status from AABB and FACT-Netcord. FACT-Netcord
is universally recognised as one of the gold standards
for cord blood banking. In October 2015, Cordlife was
selected as Stem Cell Company of the Year in Singapore
by Frost & Sullivan. We were also named as runner-up
of the 16th SIAS Investors’ Choice Award, Singapore
Corporate Governance Award 2015, Mid and Small
Category. The award was presented in recognition of
our efforts to adopt best practices and holding ourselves
up to the highest standards of corporate governance. In
November 2015, we were named by Forbes Asia as one
of the “Best under a Billion” companies. The award paid
tribute to the entrepreneurial success of 200 best small
and mid-sized public companies in Asia. We are humbled
to receive these awards, which serve as a validation and
af rmation of our business strategies and corporate
values.
Next Phase of Growth
We will continue to build on our competitive strengths
as the leading mother and child consumer healthcare
company. We believe the appointment of new leadership,
alongside their vast experience in the healthcare industry,
has greatly strengthened our management team as well
as widened our medical network, to take us to even
greater heights.
Amidst the ever-changing healthcare landscape, it is
important for us to stay united as a team and remain
focused on our key growth strategies to drive expansion
in scale and scope. We will continue to innovate and
increase our range of consumer healthcare products
and services as well as continue to set footprints into the
fastest growing Asian countries while staying entrenched
in our existing markets. Backed by solid cash holdings,
we are also on the lookout for new and accretive
acquisitions to enhance our market leadership in the
consumer healthcare industry.
Despite challenging market conditions, we have managed
to stay the course. I believe the management team will
steer Cordlife along the trajectory that we have set for
ourselves.
Appreciation
I would like to take this opportunity to thank Mr Jeremy
Yee, who had resigned on March 21, 2016, for his
contributions to the Group over the years, as well as
Mr Gary Xie and Mr Christopher Ho, who resigned on
September 30, 2016 and October 4, 2016, respectively.
On behalf of the Board, I wish them all the best.
Our continuing story of success is the culmination of
support received from various stakeholders including
our business associates as well as the management and
staff. On behalf of the Board, I would also like to express
my appreciation to all shareholders for giving us your
continued support.
Lastly, I would like to thank the parents who have entrusted
their babies’ precious cord blood and cord lining with
us and those who chose our diagnostics services. We
will continue to push our limits to deliver high quality
healthcare products and services to the market.
DR HO CHOON HOU
Chairman and Non-Executive Director
